Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2018 08:00 ET | Source: Albireo, Inc.

Albireo to Receive More than $55 Million(1) in Nondilutive Cash Payments

— Elobixibat approved in Japan for the treatment of chronic constipation — — Albireo innovation leads to world’s first approved ileal bile acid transporter (IBAT) inhibitor — BOSTON, Jan. 19, 2018 ...
January 03, 2018 08:00 ET | Source: Albireo, Inc.

Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan

— Albireo subsidiary eligible to receive up to $60 million under agreement — — Decision on Japanese New Drug Application for elobixibat expected in first half of 2018 — BOSTON, Jan. 03, 2018 ...
December 29, 2017 08:00 ET | Source: Albireo, Inc.

Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant...
November 14, 2017 08:00 ET | Source: Albireo, Inc.

Albireo Reports Third Quarter 2017 Financial Results

— Executing towards planned A4250 Phase 3 PFIC trial —— Decision on potential approval of elobixibat in Japan expected in the first half of 2018 — BOSTON, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Albireo...
November 09, 2017 08:00 ET | Source: Albireo, Inc.

Albireo to Present at the Jefferies 2017 London Healthcare Conference

BOSTON, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron...
October 20, 2017 08:00 ET | Source: Albireo, Inc.

Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting® 2017

— A4250 reduced serum bile acids and improved pruritus in most patients, exhibited a favorable overall tolerability profile — — Albireo to conduct Phase 3 study in children with progressive...
October 16, 2017 08:00 ET | Source: Albireo, Inc.

Albireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis

BOSTON, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it...
October 03, 2017 08:00 ET | Source: Albireo, Inc.

Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017

BOSTON, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced data from...
September 28, 2017 08:00 ET | Source: Albireo, Inc.

Albireo Elects Roger Jeffs to Board of Directors

— Former CEO of rare disease company brings significant orphan drug development and commercialization experience — BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a...
September 26, 2017 08:00 ET | Source: Albireo, Inc.

EMA’s Paediatric Committee Agrees to Albireo’s A4250 Pediatric Investigation Plan

Agreement an essential step for a potential EU marketing authorization application Completion of PIP would provide an additional two years of market exclusivity Planned Phase 3 clinical...